Receptors, Tumor Necrosis Factor, Type II
"Receptors, Tumor Necrosis Factor, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor receptor subtype that is expressed primarily in IMMUNE SYSTEM cells. It has specificity for membrane-bound form of TUMOR NECROSIS FACTORS and mediates intracellular-signaling through TNF RECEPTOR ASSOCIATED FACTORS.
Descriptor ID |
D047889
|
MeSH Number(s) |
D12.776.543.750.705.852.760.798 D23.050.301.264.035.910 D23.101.100.110.916
|
Concept/Terms |
Receptors, Tumor Necrosis Factor, Type II- Receptors, Tumor Necrosis Factor, Type II
- Receptors, Tumor Necrosis Factor, Member 1B
- TNF-R2
- TNF-R75
- TNF-RII
- TNFR p75
- Tumor Necrosis Factor Receptor 75
- Tumor Necrosis Factor Receptor 2
- TNFR2
- Tumor Necrosis Factor Receptor Type 2
- Tumor Necrosis Factor Receptor Type II
- Antigens, CD120b
- CD120b Antigens
- TNFRSF1B Receptor
- Receptor, TNFRSF1B
- Tumor Necrosis Factor Receptor Superfamily, Member 1B
- CD 120b Antigen
- 120b Antigen, CD
- Antigen, CD 120b
- CD120b Antigen
- Antigen, CD120b
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor, Type II".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Receptors, Tumor Necrosis Factor, Type II [D12.776.543.750.705.852.760.798]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Receptors, Tumor Necrosis Factor, Type II [D23.050.301.264.035.910]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Receptors, Tumor Necrosis Factor, Type II [D23.101.100.110.916]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor, Type II".
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type II" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2003 | 0 | 2 | 2 | 2008 | 0 | 1 | 1 | 2009 | 1 | 1 | 2 | 2011 | 0 | 1 | 1 | 2013 | 1 | 0 | 1 | 2015 | 1 | 0 | 1 | 2016 | 1 | 0 | 1 | 2018 | 1 | 0 | 1 | 2019 | 1 | 1 | 2 | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type II" by people in Profiles.
-
Liu CY, Tam SS, Huang Y, Dubé PE, Alhosh R, Girish N, Punit S, Nataneli S, Li F, Bender JM, Washington MK, Polk DB. TNF Receptor 1 Promotes Early-Life Immunity and Protects against Colitis in Mice. Cell Rep. 2020 10 20; 33(3):108275.
-
Paschalis EI, Taniguchi EV, Chodosh J, Pasquale LR, Colby K, Dohlman CH, Shen LQ. Blood Levels of Tumor Necrosis Factor Alpha and Its Type 2 Receptor Are Elevated in Patients with Boston Type I Keratoprosthesis. Curr Eye Res. 2019 06; 44(6):599-606.
-
Garudadri S, Woodruff PG, Han MK, Curtis JL, Barr RG, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G, Dransfield MT, Hansel NN, Paine R, Krishnan JA, Peters SP, Hastie AT, Martinez FJ, O'Neal WK, Couper DJ, Alexis NE, Christenson SA. Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. Chest. 2019 05; 155(5):908-917.
-
Spinale FG, Meyer TE, Stolen CM, Van Eyk JE, Gold MR, Mittal S, DeSantis SM, Wold N, Beshai JF, Stein KM, Ellenbogen KA. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
-
Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SV, Weidenbusch M, Grigorescu M, Lech M, Eltrich N, Müller L, Hans W, Hrabe de Angelis M, Vielhauer V, Hoppe B, Asplin J, Burzlaff N, Herrmann M, Evan A, Anders HJ. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. J Am Soc Nephrol. 2017 Mar; 28(3):761-768.
-
Punit S, Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis. Gastroenterology. 2015 Oct; 149(4):993-1005.e2.
-
Su L, Nalle SC, Shen L, Turner ES, Singh G, Breskin LA, Khramtsova EA, Khramtsova G, Tsai PY, Fu YX, Abraham C, Turner JR. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology. 2013 Aug; 145(2):407-15.
-
Murley JS, Baker KL, Miller RC, Darga TE, Weichselbaum RR, Grdina DJ. SOD2-mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and amifostine. Free Radic Biol Med. 2011 Nov 15; 51(10):1918-25.
-
Petrof EO, Claud EC, Sun J, Abramova T, Guo Y, Waypa TS, He SM, Nakagawa Y, Chang EB. Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function. Inflamm Bowel Dis. 2009 Oct; 15(10):1537-47.
-
Sibai B, Romero R, Klebanoff MA, Rice MM, Caritis S, Lindheimer MD, Van Dorsten JP, Landon M, Miodovnik M, Dombrowski M, Meis P. Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol. 2009 Jun; 200(6):630.e1-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|